Lois Larsen

3.6k total citations · 2 hit papers
54 papers, 2.7k citations indexed

About

Lois Larsen is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Lois Larsen has authored 54 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hepatology, 19 papers in Epidemiology and 15 papers in Infectious Diseases. Recurrent topics in Lois Larsen's work include Hepatitis C virus research (25 papers), HIV/AIDS drug development and treatment (15 papers) and Liver Disease Diagnosis and Treatment (13 papers). Lois Larsen is often cited by papers focused on Hepatitis C virus research (25 papers), HIV/AIDS drug development and treatment (15 papers) and Liver Disease Diagnosis and Treatment (13 papers). Lois Larsen collaborates with scholars based in United States, United Kingdom and Germany. Lois Larsen's co-authors include Thomas Podsadecki, Edward Tam, Barry Bernstein, Kris V. Kowdley, Kristof Chwalisż, Junyuan Xiong, Cynthia Mattia‐Goldberg, David R. Nelson, Fred Poordad and Jordan J. Feld and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Lois Larsen

53 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 686 citations Jordan J. Feld, Kris V. Kowdley et al. New England Journal of Medicine profile →
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 395 citations Stefan Zeuzem, Ira M. Jacobson et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Lois Larsen

Since Specialization

Citations

This map shows the geographic impact of Lois Larsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lois Larsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lois Larsen more than expected).

Fields of papers citing papers by Lois Larsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lois Larsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lois Larsen. The network helps show where Lois Larsen may publish in the future.

Co-authorship network of co-authors of Lois Larsen

This figure shows the co-authorship network connecting the top 25 collaborators of Lois Larsen. A scholar is included among the top collaborators of Lois Larsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lois Larsen. Lois Larsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon 2025 ·Alimentary Pharmacology & Therapeutics ·Hashem B. El‐Serag, Hao T. Duong, (unknown), Fasiha Kanwal, Deanna Hill, Margaret Burroughs, (unknown), Barbara Haber, Lois Larsen, John Marcinak, Lani R. Wegrzyn, (unknown), (unknown), (unknown)	1
2	Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir 2021 ·Journal of Hepatology ·Gary P. Wang, Gretja Schnell, Jens Kort, Gurjit Sidhu, (unknown), Rakesh Tripathi, Lois Larsen, (unknown), (unknown), (unknown), (unknown), Joan A. Whitlock, (unknown), Joy Peter, Michael Fried, David R. Nelson	1
3	Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy 2019 ·Gastroenterology ·Anna S. Lok, Mark Sulkowski, Jens Kort, Ira Willner, K. Rajender Reddy, Mitchell L. Shiffman, Mohamed A. Hassan, Brian L. Pearlman, Federico Hinestrosa, Ira M. Jacobson, Giuseppe Morelli, Joy Peter, Monika Vainorius, (unknown), Michael Fried, Gary P. Wang, Wenjing Lü, Lois Larsen, David R. Nelson	34
4	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection 2019 ·Journal of Gastroenterology ·Atsushi Naganuma, Kazuaki Chayama, Kazuo Notsumata, Edward Gane, Graham R. Foster, David Wyles, Paul Y. Kwo, Eric D. Crown, (unknown), Federico Mensa, Tetsuya Otani, Lois Larsen, Margaret Burroughs, Hiromitsu Kumada	16
5	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks 2015 ·Journal of Hepatology ·Jordan J. Feld, Christophe Moreno, Roger Trinh, Edward Tam, Stefan Bourgeois, Yves Horsmans, Magdy Elkhashab, David Bernstein, Ziad Younes, Robert Reindollar, Lois Larsen, Bo Fu, (unknown), Akshanth R. Polepally, Andreas Pangerl, Nancy S. Shulman, Fred Poordad	110
6	Ribavirin does not impact health-related quality of life (HRQOL) in patients on Ombitasvir/ Paritaprevir /Ritonavir and dasabuvir at the end of 12-week treatment in Treatment-NaÏve adults with Genotype 1A (GT1A) Chronic Hepatitis C 2015 ·Value in Health ·(unknown), David Bernstein, Lois Larsen, Yan Luo, (unknown), Timothy Juday	2
7	Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty 2014 ·Clinical Drug Investigation ·Nael M. Mostafa, Balakrishna Hosmane, Lois Larsen, Kristof Chwalisż, Yi‐Lin Chiu, Rajendra Pradhan	3
8	Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin breakdown → 2014 ·New England Journal of Medicine ·Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, Samuel H. Sigal, David R. Nelson, Dorothy H. Crawford, Ola Weiland, Humberto Aguilar, Junyuan Xiong, Edward Tam, (unknown), Lois Larsen, Thomas Podsadecki, Barry Bernstein	686
9	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 2014 ·New England Journal of Medicine ·Kris V. Kowdley, Eric Lawitz, Fred Poordad, Daniel E. Cohen, David R. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Y. Kwo, Graham R. Foster, Mark Sulkowski, Wangang Xie, Edward Tam, (unknown), Lois Larsen, Amit Khatri, Thomas Podsadecki, Barry Bernstein	185
10	Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin breakdown → 2014 ·New England Journal of Medicine ·Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal, Rui Tato Marinho, Fred Poordad, Marc Bourlière, Mark Sulkowski, Heiner Wedemeyer, Edward Tam, Paul Desmond, Donald M. Jensen, Adrian M. Di Bisceglie, Peter Varunok, Tarek Hassanein, Junyuan Xiong, (unknown), Lois Larsen, Thomas Podsadecki, Barry Bernstein	395
11	A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 2013 ·Journal of Hepatology ·Eric Lawitz, Fred Poordad, Kris V. Kowdley, Daniel E. Cohen, Thomas Podsadecki, (unknown), Lois Larsen, Rajeev Menon, Gennadiy Koev, Rakesh Tripathi, Edward Tam, Barry Bernstein	55
12	Validation of the Menstrual Pictogram in Women With Leiomyomata Associated With Heavy Menstrual Bleeding 2012 ·Reproductive Sciences ·Lois Larsen, Karin S. Coyne, Kristof Chwalisż	12
13	Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer 2011 ·Prostate Cancer and Prostatic Diseases ·Aaron Spitz, Jay M. Young, Lois Larsen, Cynthia Mattia‐Goldberg, J. Donnelly, Kristof Chwalisż	39
14	Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study 2011 ·International Journal of Pediatric Endocrinology ·Peter A. Lee, E. Kirk Neely, John S. Fuqua, (unknown), Lois Larsen, Cynthia Mattia‐Goldberg, Kristof Chwalisż	35
15	Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants 2010 ·Quality of Life Research ·Kathleen W. Wyrwich, Reema Mody, Lois Larsen, Misun Lee, Neesha Harnam, Dennis A. Revicki	9
16	Leuprolide Acetate 1-Month Depot for Central Precocious Puberty: Hormonal Suppression and Recovery 2010 ·International Journal of Pediatric Endocrinology ·E. Kirk Neely, Peter A. Lee, C Bloch, Lois Larsen, (unknown), Cynthia Mattia‐Goldberg, Kristof Chwalisż	45
17	Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed‐release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis 2009 ·Alimentary Pharmacology & Therapeutics ·David C. Metz, Colin W. Howden, María Claudia Pérez, Lois Larsen, Janet O’Neil, Stuart Atkinson	57
18	Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief 2009 ·Alimentary Pharmacology & Therapeutics ·Colin W. Howden, Lois Larsen, María Claudia Pérez, Robert Palmér, Stuart Atkinson	34
19	A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata 2007 ·Fertility and Sterility ·Kristof Chwalisż, Lois Larsen, Cynthia Mattia‐Goldberg, Anthony Edmonds, W. Elger, Craig A. Winkel	114
20	Therapeutic Potential for the Selective Progesterone Receptor Modulator Asoprisnil in the Treatment of Leiomyomata 2004 ·Seminars in Reproductive Medicine ·Kristof Chwalisż, Deborah A. DeManno, (unknown), Lois Larsen, Cynthia Mattia‐Goldberg, (unknown)	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact